A Phase 3 interventional study of Cefepime-zidebactam (FEP-ZID) and Meropenem in Complicated Urinary Tract Infection and Acute Pyelonephritis, sponsored by Wockhardt. Completed at 48 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by Wockhardt · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 3, randomized, double-blind, multicenter, non-inferiority study to evaluate the efficacy, safety, and tolerability of FEP-ZID vs. meropenem in the treatment of hospitalized adults with cUTI or AP.
Approximately 528 hospitalized adult subjects (≥ 18 years of age) diagnosed with cUTI or AP will be enrolled in the study. The diagnosis of cUTI or AP will be based on a combination of clinical symptoms and signs plus the presence of pyuria. The total duration of treatment with study drug is 7 to 10 days. Each subject must remain hospitalized during the study drug treatment period; no outpatient parenteral antibiotic therapy is allowed.
79 studies on the registry are indexed under Pyelonephritis; 12 are open to participants now.
This study's enrollment of 530 is above the median of 175 across 62 interventional studies indexed under Pyelonephritis.
Browse Pyelonephritis studies →Wockhardt is the lead sponsor of 39 studies on the registry; 3 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 1 (11%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Cefepime-zidebactam (FEP-ZID)
Drug: Meropenem
3 g (2 g FEP + 1 g ZID) IV q8h
1 g IV q8h
Percentage of Subjects With Overall Success at Test-of-Cure
Overall success is defined as complete resolution of cUTI or AP symptoms present at study entry (or return to premorbid state) and no new cUTI or AP symptoms together with microbiologic eradication of the bacterial pathogen found at study entry (reduced to \<1000 colony forming units or CFU/mL)
Time frame: Test Of Cure Visit (Day 17 ± 2 days)
Percentage of Subjects With Treatment-Emergent Adverse Events (TEAE)
Collection of number of adverse events.
Time frame: Day 1 to the end of study Late Follow-Up visit (LFU) (26 ± 2 days)]
Percentage of Subjects With Overall Success at End-of-Treatment
Overall success is defined as complete resolution of cUTI or AP symptoms present at study entry (or return to premorbid state) and no new cUTI or AP symptoms together with microbiologic eradication of the bacterial pathogen found at study entry (\<1000 CFU/mL)
Time frame: End of Treatment Visit (Day 7 - 10 ± 1 day)
Percentage of Subjects With Clinical Cure at End-of-Treatment
Clinical cure is defined as complete resolution of cUTI or AP symptoms present at study entry (or return to premorbid state) and no new cUTI or AP symptoms together with microbiologic eradication of the bacterial pathogen found at study entry (reduced to \<1000 CFU/mL)(CFU)/mL.
Time frame: End of Treatment Visit (Day 7 - 10 ± 1 day)
Percent of Subjects With Microbiological Eradication at End-of-Treatment
Microbiologic eradication is defined as demonstrating \<1000 CFU/mL of the bacterial pathogen found at study entry
Time frame: End of Treatment Visit (Day 7 - 10 ± 1 day)
Percentage of Subjects With Clinical Cure at Test-of-Cure
Clinical cure is defined as complete resolution of cUTI or AP symptoms present at study entry (or return to premorbid state) and no new cUTI or AP symptoms together with microbiologic eradication of the bacterial pathogen found at study entry (reduced to \<1000 CFU/mL)
Time frame: Test-of-Cure (Day 17+-2)
Percent of Subjects With Microbiological Eradication at Test-of-Cure
Microbiologic eradication is defined as demonstrating \<1000 CFU/mL of the bacterial
Time frame: Test-of-Cure (Day 17 ± 2 days)
Percentage of Subjects With Clinical Cure at Late Follow-up
Clinical cure is defined as complete resolution of cUTI or AP symptoms present at study entry (or return to premorbid state) and no new cUTI or AP symptoms together with microbiologic eradication of the bacterial pathogen found at study entry (reduced to \<1000 CFU/mL)
Time frame: Late Follow-up (Day 26 ± 2 days)
Plasma Concentration of FEP-ZID
Plasma samples from ZID-FEP-treated subjects were analyzed to determine concentrations of ZID and FEP using a validated assay. Pharmacokinetic analyses were based on the PK populations at pre-specified time points on Days 1 and 3 (+1).
Time frame: On Days 1 and 3 (+1) of dosing prior to infusion, within 15 minutes after the end of infusion, and at 3 timepoints up to 7 hours hours post infusion
| Milestone | Cefepime-zidebactam (FEP-ZID) | Meropenem |
|---|---|---|
| Started | 353 | 177 |
| Completed | 344 | 174 |
| Not completed | 9 | 3 |
Overall success is defined as complete resolution of cUTI or AP symptoms present at study entry (or return to premorbid state) and no new cUTI or AP symptoms together with microbiologic eradication of the bacterial pathogen found at study entry (reduced to \<1000 colony forming units or CFU/mL)
| Participants | Cefepime-zidebactam (FEP-ZID) | Meropenem |
|---|---|---|
| Overall Success at TOC in mMITT-STIC Population | 250 | 93 |
| Overall Failure/Indeterminate at TOC in mMITT-STIC Population | 31 | 43 |
Collection of number of adverse events.
| Participants | Cefepime-zidebactam (FEP-ZID) | Meropenem |
|---|---|---|
| Percentage of Subjects With Treatment-Emergent Adverse Events (TEAE) | 112 | 50 |
Overall success is defined as complete resolution of cUTI or AP symptoms present at study entry (or return to premorbid state) and no new cUTI or AP symptoms together with microbiologic eradication of the bacterial pathogen found at study entry (\<1000 CFU/mL)
| Participants | Cefepime-zidebactam (FEP-ZID) | Meropenem |
|---|---|---|
| Overall Success at End of Treatment (EOT) (mMITT-STIC Population) | 270 | 132 |
| Overall Failure/Indeterminate at End of Treatment (EOT) (mMITT-STIC Population) | 11 | 4 |
Clinical cure is defined as complete resolution of cUTI or AP symptoms present at study entry (or return to premorbid state) and no new cUTI or AP symptoms together with microbiologic eradication of the bacterial pathogen found at study entry (reduced to \<1000 CFU/mL)(CFU)/mL.
| Participants | Cefepime-zidebactam (FEP-ZID) | Meropenem |
|---|---|---|
| Clinical Response at End of Treatment (EOT) (mMITT-STIC Population) | 274 | 133 |
| Clinical Non-Response/Indeterminate at End of Treatment (EOT) (mMITT-STIC Population) | 7 | 3 |
Microbiologic eradication is defined as demonstrating \<1000 CFU/mL of the bacterial pathogen found at study entry
| Participants | Cefepime-zidebactam (FEP-ZID) | Meropenem |
|---|---|---|
| Microbiological Eradication at End of Treatment (EOT) (mMITT-STIC population) | 276 | 134 |
| Microbiological Persistence/Microbiological Indeterminate at (EOT) (mMITT-STIC population) | 5 | 2 |
Clinical cure is defined as complete resolution of cUTI or AP symptoms present at study entry (or return to premorbid state) and no new cUTI or AP symptoms together with microbiologic eradication of the bacterial pathogen found at study entry (reduced to \<1000 CFU/mL)
| Participants | Cefepime-zidebactam (FEP-ZID) | Meropenem |
|---|---|---|
| Clinical Cure at Test of Cure (TOC)(mMITT-STIC) | 272 | 129 |
| Clinical Failure/Indeterminate at Test of Cure (TOC)(mMITT-STIC) | 9 | 7 |
Microbiologic eradication is defined as demonstrating \<1000 CFU/mL of the bacterial
| Participants | Cefepime-zidebactam (FEP-ZID) | Meropenem |
|---|---|---|
| Microbiologic eradication at Test of Cure (TOC) (mMITT-STIC population) | 256 | 96 |
| Microbiologic persistence/indeterminate at Test of Cure (TOC) (mMITT-STIC population) | 25 | 40 |
Clinical cure is defined as complete resolution of cUTI or AP symptoms present at study entry (or return to premorbid state) and no new cUTI or AP symptoms together with microbiologic eradication of the bacterial pathogen found at study entry (reduced to \<1000 CFU/mL)
| Participants | Cefepime-zidebactam (FEP-ZID) | Meropenem |
|---|---|---|
| Sustained Clinical Cure at Late Follow-up (LFU) in mMITT-STIC population | 264 | 128 |
| Clinical Failure/ Clinical Indeterminate at Late Follow-up (LFU) in mMITT-STIC population | 8 | 1 |
Plasma samples from ZID-FEP-treated subjects were analyzed to determine concentrations of ZID and FEP using a validated assay. Pharmacokinetic analyses were based on the PK populations at pre-specified time points on Days 1 and 3 (+1).
| ug/mL | Cefepime (FEP) | Zidebactam (ZID) |
|---|---|---|
| Day 1 at 0.25 hours | 89.400 ± 104.665 | 44.941 ± 49.569 |
| Day 1 at 2 hours | 47.375 ± 21.522 | 24.461 ± 11.252 |
| Day 3 at 0.5 hours | 19.297 ± 17.798 | 10.250 ± 9.693 |
| Day 3 at 2 hours | 61.836 ± 47.281 | 31.866 ± 22.947 |
| Day 3 at 4 hours | 38.750 ± 24.522 | 20.261 ± 13.319 |
| Day 3 at 7 hours | 23.278 ± 19.039 | 12.378 ± 10.849 |
| Day 4 at 0.5 Hours | 15.709 ± 7.998 | 8.107 ± 4.716 |
| Day 4 at 2 Hours | 54.351 ± 19.331 | 28.329 ± 10.052 |
| Day 4 at 4 Hours | 30.469 ± 9.963 | 15.664 ± 5.529 |
| Day 4 at 7 Hours | 19.173 ± 8.792 | 9.825 ± 5.029 |
Collected over Through study completion, from the signing of the Informed Consent Form (ICF) to the Late Follow-Up (LFU) visit, approximately 28 days per participant.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cefepime-zidebactam (FEP-ZID) | 0/352 (0%) | 8/352 (2.3%) | 35/352 (9.9%) |
| Meropenem | 0/177 (0%) | 1/177 (0.6%) | 19/177 (10.7%) |
| Event | Cefepime-zidebactam (FEP-ZID) | Meropenem |
|---|---|---|
| Pseudomembranous colitisInfections and infestations | 3/352 | 0/177 |
| Mechanical ileusGastrointestinal disorders | 0/352 | 1/177 |
| Anaphylactic reactionImmune system disorders | 1/352 | 0/177 |
| COVID-19Infections and infestations | 1/352 | 0/177 |
| Thoracic vertebral fractureInjury, poisoning and procedural complications | 1/352 | 0/177 |
| HyperglycaemiaMetabolism and nutrition disorders | 1/352 | 0/177 |
| Urethral stenosisRenal and urinary disorders | 1/352 | 0/177 |
| Event | Cefepime-zidebactam (FEP-ZID) | Meropenem |
|---|---|---|
| HeadacheNervous system disorders | 11/352 | 9/177 |
| DiarrhoeaGastrointestinal disorders | 15/352 | 7/177 |
| NauseaGastrointestinal disorders | 3/352 | 6/177 |
| HYPERTENTIONCardiac disorders | 11/352 | 2/177 |
| HypokalaemiaMetabolism and nutrition disorders | 10/352 | 2/177 |
| ConstipationGastrointestinal disorders | 5/352 | 2/177 |
| Abdominal pain upperGastrointestinal disorders | 4/352 | 1/177 |
| HematuriaRenal and urinary disorders | 4/352 | 0/177 |
| PainGeneral disorders | 0/352 | 2/177 |
| Decreased AppetiteMetabolism and nutrition disorders | 2/352 | 2/177 |
Baseline Analysis Population described here includes MITT (modified intend to treat)
| Age, Customized(Participants) | Cefepime-zidebactam (FEP-ZID) | Meropenem | Total |
|---|---|---|---|
| >=18 years in MITT population | 352 | 177 | 529 |
| Sex: Female, Male(Participants) | Cefepime-zidebactam (FEP-ZID) | Meropenem | Total |
|---|---|---|---|
| Female | 155 | 79 | 234 |
| Male | 197 | 98 | 295 |
| Race/Ethnicity, Customized(Participants) | Cefepime-zidebactam (FEP-ZID) | Meropenem | Total |
|---|---|---|---|
| White | 311 | 158 | 469 |
| Asian Non Chinese | 93 | 13 | 106 |
| Asian Chinese | 12 | 5 | 17 |
| American Indianor Alaskan Native | 6 | 1 | 7 |
| Region of Enrollment(participants) | Cefepime-zidebactam (FEP-ZID) | Meropenem | Total |
|---|---|---|---|
| United States | 6 | 4 | 10 |
| China | 12 | 5 | 17 |
| Poland | 36 | 21 | 57 |
| Mexico | 8 | 6 | 14 |
| Slovakia | 12 | 9 | 21 |
| Bulgaria | 166 | 74 | 240 |
| Lithuania | 67 | 26 | 93 |
| Estonia | 22 | 19 | 41 |
| India | 23 | 13 | 36 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2022 to primary completion in Nov 2024, 26 months.
Results were first posted in May 2026, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cefepime-zidebactam